#ChineseBiotech
At BIO 2026, biotech executives grappled with three critical challenges: rising Chinese biotech competition, uncertain AI profitability in drug disc…

#AIdrugdiscovery #BIO2026 #Biotech #Chinesebiotech #Healthpolicy

#AIdrugdiscovery #BIO2026 #Biotech #Chinesebiotech #Healthpolicy

https://news.g…
Biotech Industry at Crossroads: BIO 2026 Reveals Key Challenges
At BIO 2026, biotech executives grappled with three critical challenges: rising Chinese biotech competition, uncertain AI profitability in drug disc… #AIdrugdiscovery #BIO2026 #Biotech #Chinesebiotech #Healthpolicy
news.gmj.ge
August 20, 2026 at 3:29 AM
To explore the changing #globallandscape of #drugdevelopment, Vibe Bio co-founder and CEO Alok Tayi recently had a conversation with Dr. Kanya Rajangam about the potential for #Chinesebiotech assets and programs in the US market.

Learn more in this post: vibebio.com/blog/chinese...
Chinese biotechs & assets, a Q&A with Kanya Rajangam, MD, PhD
Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks.
vibebio.com
March 7, 2025 at 5:05 PM
More Chinese drugmakers are moving beyond GLP-1s, adopting new strategies to capture a larger share of the global diabetes market.

longevity.technology/news/more-ch...

#DiabetesInnovation #ChineseBiotech #GLP1Alternatives #Healthspan #longevity #PrecisionMedicine #MetabolicHealth #BiotechTrends
January 28, 2026 at 4:42 PM